نتایج جستجو برای: alteplase

تعداد نتایج: 6831  

Journal: :The Annals of pharmacotherapy 2003
James M Zacharias Christine P Weatherston Candace R Spewak Lavern M Vercaigne

BACKGROUND The use of central venous catheters as a source of vascular access in patients undergoing hemodialysis may be complicated by thrombosis. Frequently, thrombolytics are used in an attempt to reestablish blood flow through partially or completely occluded catheters. OBJECTIVE To compare the efficacy of alteplase (recombinant tissue plasminogen activator) versus urokinase in reestablis...

2016
Grant Mair Rüdiger von Kummer Zoe Morris Anders von Heijne Nick Bradey Lesley Cala André Peeters Andrew J. Farrall Alessandro Adami Gillian Potter Geoff Cohen Peter A.G. Sandercock Richard I. Lindley Joanna M. Wardlaw Peter Sandercock Richard I Lindley Joanna M Wardlaw Colin Baigent David Chadwick Pippa Tyrrell Gordon Lowe Martin Dennis Karen Innes Heather Goodare Graeme J Hankey Karl Matz Michael Brainin Gord Gubitz Stephen J Phillips Stefano Ricci Antonio Arauz Eivind Berge Karsten Bruins Slot Anna Czlonkowska Adam Kobayashi Manuel Correia Phillippe Lyrer Stefan Engelter Veronica Murray Andreas Terent Bo Norrving Per Wester Graham Venables Andrew Farrall Andre Peeters Robin Sellar Philip White Andrew Demchuk Matthew Adams Bernard Yan G Venables C Blank H Bowler C Doyle K Endean K Harkness E Parker M Randall C Roffe N Ahmad A Arora S Brammer J Chembala B Davies S Ellis E Epstein K Finney C Jackson C Jadun R Kinston H Maguire I Memon I Natarajan M Poulson R Sanyal S Sills A Vreeburg E Ward P Sandercock R Al-Shahi Salman R Davenport M Dennis P Hand S Hart I Kane S Keir M MacLeod L McKinlay H Milligan E Sandeman J Stone C Sudlow P Taylor J Wardlaw C Warlow W Whiteley A Williams M Brown B Athwal V Bassan N Bhupathiraju J Bowler C Davie D Doig R Erande S Gilbert L Ginsberg R Greenwood S Gregoire N Harding N Losseff R Luder N Passeron R Perry P Rayson R Simister S Stone D Werring J Barrett H Aitken S Cherian R Davis S Downham L Godd V Gott D Jose V Little D Lowe L Luxford M McGrory P Owings N Price J Richards G Sangster J Sherlock S Vargese I Wakefield P Weir P Guyler T Attygale S Chandler L Coward S Feasey C Khuoge T Loganathan S Martin A O'Brien D Sinha V Thompson S Tysoe R Walsh K Metcalf J Cochius R Fulcher N Gange C Green J Jagger M Lee P Myint J Potter G Ravenhill S Shields N Shinh T Staunton E Thomas W Woodward P Worth N Wyatt W Sunman P Bath P Berman J Clarke C Gaynor F Hammonds R Harwood K Mitchell S Munshi S Pacey A Shetty N Sprigg H Stear G Subramanian A Wills A Rudd H Audebert A Bhalla J Birns R Chowdhury G Cluckie I Davies C Gibbs P Holmes N Mitchell F Schiavone E White M Yeung A Mehrzad V Baliga E Brown L Burnside B Esisi J Kent P Orr D Stead E Wayman R Durairaj C Cullen R Kumar H Martin D McDowell A Sharma V Sutton R White T Hughes K Ali J Anderson K Baker K Bethune M Booth M Cossburn S Halpin M Hourihan E Marsh K Peall R Powell H Shetty M Wardle M Williams K Muhiddin J Beavan M Clarke R Donneley S Elliott P Fox P Gorman M Harper M Mangoyana L Mills L Wright L Warburton J Baron P Barry D Day T Harold P Martin J Mitchell E O'Brien J Rycarte M Turnham G Cloud L Choy B Clarke C Griffin O Halse I Jones F Kennedy U Khan R Lewis A Loosemore C Lovelock H Markus B Moynihan J O'Reilly O Paul A Pereira M Punter P Rich D Rolfe M James J Bell A Bowring L Boxall J Cageao H Eastwood S Elyas F Hall S Harries A Hemsley S Jackson S Keenan P Mudd A Sekhar D Strain J Sword N Wedge M Bruce A Joyson M Kemp K McMullan J Reid O Robb J Webster S Wilkinson P Sharma P Bentley H Jenkins A Kar T Sachs D Cohen R Bathula J Devine M Mpelembue D Hargroves I Balogun L Cowie A Maidment D Rand J Rowe H Rudenko D Smithard L Wray J Paterson J Brown J Hampton S Jamieson R Rose A Volans K Chatterjee G Abbott R Brookes C Castle C Kelly S Leason A Nallasivan A Sen D Collas M Cottle N Damani P Jacob D Oza A Kenton N Adab L Aldridge H Allroggen Y Brown R Cross L Galvin K Ghosh A Grubneac A Lindahl H Mehta M Pritchard C Randall P Ray A Shehu S Thelwell D Jenkinson T Black O David J Kwan A Orpen C Ovington D Tiwari Z ud Din Babar A Hassan A Bailey J Bamford C Bedford R Bellfield J Cooper L Dunsmure J Greig M Keeling L Mandizvidza J Rankine E Roberts P Wanklyn T Webb S Williamson J Coyle S Crane C Croser P Duffey R Evans E Iveson G Kitching M Porte C Rhymes D Barer M Armstrong M Bokhari T Cassidy B McClelland G Gunathilagan P Dolke S Jain S Jones L Rosser G Thomas C White P Sanmuganathan C Scholtz E Stratford M O'Donnell H Goddard G Hoadley J Howard S Leach J McIlmoyle A Stewart A Strain F Huwez P Croot N Gadi N Mguni U Umasankar G Mead B Chapman A Coull A Kinnear B Morrow F Morrow D Ames J Ball S Bannerjee J Chataway K Rashed C Buckley D Donaldson D Hayward C Lawson L Sekaran K Bharaj F Justin G Jutlla D Phiri S Sethuraman M Tate D Sandler P Carr G Jones J Lyons K Warren L Kalra A Davis J Jarosz D Manawadu L Sztriha D Chadha A Holford P Willcoxson L Shaw D Button A Cunningham L Dow J Dutson T Hall C Hardy N Jakeman P Kaye B Madigan K O'Brien D Pressdee M Price L Robinson C Taylor D Williamson J McCormack C Stretton P Earnshaw S Bruce C Church S Desai M Myint N Watt C Price H Graham R Lakey K Mitchelson P Murphy L Ball S Caine J Dovey J Hughes A Steele K Dizayee A Brown T Chattopadhyay J Cheetham H Cochrane A Datta M Datta-chaudhuri C Fox D Kilroy S Krishnamoorthy F Levy S Metha P Ngoma B Venkatesh R Gautam N Henderson M Jones S Murphy G Spurling I Wiggam C Boyd K Fullerton P Gray M Kinnaird S MacNair

OBJECTIVE To investigate whether the location and extent of the CT hyperdense artery sign (HAS) at presentation affects response to IV alteplase in the randomized controlled Third International Stroke Trial (IST-3). METHODS All prerandomization and follow-up (24-48 hours) CT brain scans in IST-3 were assessed for HAS presence, location, and extent by masked raters. We assessed whether HAS gre...

2013
Erich Bluhmki Barbara Tilley Gregory Albers Colin Baigent Stephen Davis Geoffrey Donnan James Grotta Werner Hacke Maarten Lansberg Richard Lindley Patrick Lyden Peter Sandercock Danilo Toni Nils Wahlgren Joanna Wardlaw William White

RATIONALE Thrombolysis with intravenous alteplase is both effective and safe when administered to particular types of patient within 4·5 hours of having an ischemic stroke. However, the extent to which effects might vary in different types of patient is uncertain. AIMS AND DESIGN We describe the protocol for an updated individual patient data meta-analysis of trials of intravenous alteplase, ...

Journal: :Medical archives 2013
Nerma Resic Azra Durak-Nalbantic Alen Dzubur Enisa Hodzic Mehmed Kulic Nirvana Sabanovic-Bajramovic Elmedina Jahic

INTRODUCTION Usage of fibrinolytic therapy leads to reperfusion of the occluded coronary arteries, rescue of ventricle myocardium and successful recovery of patient. GOAL The objective of this study was to compare the reperfusion effect of streptokinase and alteplase in acute myocardial infarction (AMI) by analyzing echocardiographic parameters and post-coronarography treatment. PATIENTS AN...

Journal: :The American journal of cardiology 1997
K Pietilä W T Hermens A Harmoinen T Baardman A Pasternack E J Topol M L Simoons

Peak serum C-reactive protein concentrations were measured in 146 patients randomized to receive streptokinase, alteplase, or a combination of streptokinase and alteplase in the GUSTO-I trial. Those receiving alteplase treatment had lower values than those receiving streptokinase or the combination treatment. Irrespective of treatment, complete reperfusion of the infarct-related artery (TIMI gr...

Journal: :Journal of vascular and interventional radiology : JVIR 2006
Martha Blaney Violet Shen John A Kerner Brian R Jacobs Sarah Gray Jennifer Armfield Charles P Semba

PURPOSE Alteplase is approved for use in the restoration of function to occluded central venous access devices (CVADs); however, there are few prospective studies in children. This study was undertaken to evaluate the safety and efficacy of alteplase in the treatment of CVAD occlusions in a pediatric population. MATERIALS AND METHODS A prospective, multicenter, open-label, single-arm study ev...

Journal: :Current hematology reports 2002
William D Haire

BACKGROUND The use of thrombolytic agents in the treatment of hemodynamically stable patients with acute submassive pulmonary embolism remains controversial. METHODS We conducted a study of patients with acute pulmonary embolism and pulmonary hypertension or right ventricular dysfunction but without arterial hypotension or shock. The patients were randomly assigned in double-blind fashion to ...

Journal: :Stroke 2011
Yoshinari Nagakane Soren Christensen Caspar Brekenfeld Henry Ma Leonid Churilov Mark W Parsons Christopher R Levi Kenneth S Butcher Andre Peeters P Alan Barber Christopher F Bladin Deidre A De Silva John Fink Thomas E Kimber David W Schultz Keith W Muir Brian M Tress Patricia M Desmond Stephen M Davis Geoffrey A Donnan

BACKGROUND AND PURPOSE the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) was a prospective, randomized, double-blinded, placebo-controlled, phase II trial of alteplase between 3 and 6 hours after stroke onset. The primary outcome of infarct growth attenuation on MRI with alteplase in mismatch patients was negative when mismatch volumes were assessed volumetrically, without coregist...

Journal: :Stroke 2011
Jennifer S Lees Nishant K Mishra Monica Saini Patrick D Lyden Ashfaq Shuaib

BACKGROUND AND PURPOSE Hypothermia is neuroprotective in ischemic stroke models. The influence of baseline body temperature on outcomes after thrombolytic therapy is unclear. We examined outcomes after alteplase treatment across baseline body temperature for patients with ischemic stroke in data held within the Virtual International Stroke Trials Archive (VISTA; 1998 to 2007). METHODS We coll...

Journal: :Hospital pharmacy 2015
Stephen P Sapienza Darrin R Ciaschini

PURPOSE To evaluate the efficacy and economic impact of a maximum of 2 doses of intraluminal volume 1 mg/1 mL dose alteplase for the clearance of occluded peripherally inserted central catheter (PICC) lines at a long-term acute care hospital (LTACH). METHODS Open-label, nonrandomized quasi-experimental trial taking place over a 3-month period from December 2013 to March 2014. Patients had a s...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید